Cameron's Law makes two changes to help people with rare diseases. First, it doubles a tax credit that helps pharmaceutical companies develop drugs for uncommon illnesses. Right now, companies get a 25% tax credit when they spend money testing drugs for rare diseases—this bill increases that to 50%. This means companies will get more money back from the government for their research spending, which could encourage them to invest more in treatments for conditions that don't affect many people and might otherwise be ignored because they're not profitable. Second, the bill asks the Centers for Disease Control and Prevention to study whether the U.S. can better track rare diseases across the country. This means figuring out how many people have these conditions, where they live, and how the diseases spread—information that's currently scattered and hard to find. Better tracking could help doctors diagnose patients faster and help researchers understand these diseases more completely. Overall, this law aims to make it more attractive for companies to develop treatments for rare illnesses while also improving how the government monitors and understands these conditions.

Cameron’s Law

Gottheimer, Josh

Cameron's Law This bill increases the rate of the tax credit for clinical testing expenses for rare diseases or conditions from 25% to 50% (orphan drug tax credit). The bill also requires the Centers for Disease Control and Prevention to complete a study to evaluate the feasibility of enhancing and expanding the infrastructure to track the epidemiology of rare diseases or conditions.